US20050014825A1 - Preparation and use of solidified oils - Google Patents
Preparation and use of solidified oils Download PDFInfo
- Publication number
- US20050014825A1 US20050014825A1 US10/913,428 US91342804A US2005014825A1 US 20050014825 A1 US20050014825 A1 US 20050014825A1 US 91342804 A US91342804 A US 91342804A US 2005014825 A1 US2005014825 A1 US 2005014825A1
- Authority
- US
- United States
- Prior art keywords
- composition
- oil
- matter according
- solid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/01—Other fatty acid esters, e.g. phosphatides
- A23D7/013—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- the present invention relates to a method of solidifying at least one oil by the addition of at least one solid fat and, more particularly, to a method of forming a semi-solid paste containing a high concentration of an oil which is normally liquid.
- the present invention further relates to a soft solid mixture which typically includes 50% or more ethyl esters of natural fatty acids and 50% or less solid fat and, more particularly, to a semi-solid mixture containing fish oil or another source of fat soluble vitamins, including, but not limited to, purified vitamin E.
- the present invention further relates to a method of using an oil for purposes including, but not limited to, nutritional supplementation, cosmetic treatment, and medical treatment.
- oils which are nutritionally important substances exist as fluid oils. Their handling, storage and application is therefore limited to containers (e.g., cooking oil) or capsules (e.g., vitamin E).
- containers e.g., cooking oil
- capsules e.g., vitamin E
- oils can be handled in a solidified form by the addition of large excess of solids like starch, calcium carbonate, lactose etc., which is a common practice in the pharmaceutical industry. After addition of solids, the oils may be pressed into tablets. Owing to the physical size limit of tablets or capsules designed to be consumed by humans, high dose therapy with purified vitamin E, or with substances such as wheat germ oil or fish oil has been problematic because treatment regimens require daily consumption of tens of tablets or capsules.
- vitamin E or fish oil which is rich in omega-3 polyunsaturated fatty acids ( ⁇ -3 PUFA)
- ⁇ -3 PUFA omega-3 polyunsaturated fatty acids
- a method of solidifying liquid oils comprising the steps of (a) mixing at least one liquid oil and at least one solid fat, thereby forming a mixture of the at least one liquid oil and the at least one solid fat; and (b) transforming the mixture into a homogeneous consistency.
- composition of matter comprising a mixture of at least one liquid oil and at least one solid fat.
- composition of matter comprising a mixture of at least one ethyl ester of a natural fatty acid and at least one solid fat.
- a method of using at least one liquid oil for a purpose selected from the group consisting of nutritional supplementation, cosmetic treatment, use as a food additive, medical treatment, medical prophylaxis and cosmetic prophylaxis comprising the steps of using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the purpose.
- a method of using at least one liquid oil for prevention or treatment of a medical condition selected from the group consisting of cancer, hypertriglyceridemia, hypo HDL, high cholesterol, hyperinsulinemia and hyperglycemia comprising the step of using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the prevention or treatment.
- the composition of matter has a homogeneous consistency.
- the at least one liquid oil is at least 50% of the mixture by weight.
- composition of matter further comprising at least one additional ingredient.
- the at least one additional ingredient includes at least one flavoring agent.
- the at least one additional ingredient includes at least one odorant.
- the at least one solid fat is selected from a group of solid fats consisting of bee wax, propolis, butter, artificially hydrogenated vegetable oil, palm oil, cocoa butter, rendered animal fat and lanolin.
- the at least one solid fat is a synthetic polyester of fatty acids and a saccharide.
- the saccharide is selected from the group of saccharides consisting of sorbitol, glucose, fructose, lactose, mannose, ribose and deoxyribose.
- the at least one solid fat is a mixture of saccharide is sucrose and further wherein the fatty acid is selected from the group consisting of polypalmitate and polystearate.
- the at least one liquid oil includes omega-3 polyunsaturated fatty acids ( ⁇ -3 PUFA).
- the at least one liquid oil includes ⁇ -tocopherol (vitamin E).
- the present invention successfully addresses the shortcomings of the presently known configurations by providing nutritionally or medically important liquid oils at high concentration In a semi-solid form in order to facilitate better patient compliance with proposed treatment regimens.
- FIG. 1 is a bar-graph presenting the effect of consuming a bee wax solidified fish oil containing 60% ⁇ -3 PUFA according to t present invention on lung metastasis.
- Mice C57BL/6J were kept in filter-covered plastic cages (10 mice per cage) and were fed ad libitum with a basal oil-free standard diet supplemented with 5% by weight of either bee wax solidified fish oil (FO) or bee wax solidified soybean oil (SO). After two weeks mice were inoculated in the footpad with 5 ⁇ 10 5 cells of a highly metastatic clone (D 122) of the 3LL Lewis Lung Carcinoma cell line (Elsenbach et al, Int. J.
- D 122 highly metastatic clone
- the present invention is directed to methods for producing mixtures containing typically greater than 50% liquid oil(s) which are semi-solid or solid at room temperature and/or when refrigerated by household means.
- the present invention is further directed to compositions of matter containing typically greater than 50% liquid oil which are semi-solid or solid at room temperature and/or when refrigerated by household means.
- the present invention is further of methods of medical treatment, prophylaxis, nutritional supplementation or cosmetic treatment which employ compositions of matter containing greater than 50% oil which are semi-solid or solid at room temperature and/or when refrigerated by household means.
- the present invention can be used to increase patient compliance in therapy regimens requiring consumption of large quantities of oil by allowing preparation and presentation of the material to be ingested in a small volume and in a more palatable form than previously available.
- liquid oil refers to an oil which is a liquid in at least a portion of the temperature range of 4-25° C.
- solid fat refers to an oil which is a solid in at least a portion of the temperature range of 4-25° C.
- vegetable oil refers to any oil derived from any part of a plant, including, but not limited to, soybean oil, corn oil, rapeseed oil, olive oil, yam oil, cottonseed oil, walnut oil, peanut oil and almond oil.
- artificially hydrogenated refers to any process by which the degree of saturation of carbon to carbon double bonds may be increased, whether mechanically, physically, or chemically.
- one preferred embodiment of the present invention is solidification of fish oil by bee wax to produce a mixture containing about 80% ⁇ -3 PUFA.
- a patient requiring a daily dose of 6 grams of ⁇ -3 PUFA would therefore need to consume 10-12 grams of the resultant semi-solid paste.
- This portion of semi-solid paste would take the place of, for example, 20 capsules which typically contain about 300 mg ⁇ -3 PUFA.
- a 10-12 gram portion of solidified fish oil paste could be ingested, for example, by spreading it upon a single slice of bread.
- the semi-solid paste might be mixed with flavoring agents, including, but not limited to, smoked salmon flavor, or parmesan cheese flavor, to render it more palatable.
- flavoring agents including, but not limited to, smoked salmon flavor, or parmesan cheese flavor, to render it more palatable.
- odorants such as garlic scent or oregano scent might be added to increase palatability.
- purified vitamin E may be similarly solidified by combining it with a low calorie fat substitute.
- Advantages of using a low calorie fat substitute in compositions of matter of the present invention include, but are not limited to, keeping total caloric intake of a patient as low as possible.
- Myriad medical conditions may be treated using oils as dietary supplements.
- Examples 5 and 6 describe treatment of a cancer (in an animal model) and hyperlipidemia, respectively. These embodiments are presented as examples of a wide range of possible benefits from the present invention.
- Example 5 describes reduced tumor growth, mortality and metastatic growth in a well established murine lung cancer model in response to dietary supplementation with solidified fish oil prepared according to the method of the present invention. Extrapolation of the results to human patients suggests tremendous potential benefit. With respect to cancer patients, the method of the present invention is especially important, since these patients tend to suffer from decreased appetite and nausea. It is therefore especially important to increase palatability of medication in order to elicit compliance with a proposed treatment regimen.
- Example 6 describes the effects of administration of solidified fish oil according to the present invention to human subjects to control hyperlipidemia. After 6 weeks, treatment induced a significant reduction in triglycerides, cholesterol, insulin and glucose was observed. A concurrent increase in HDL and decrease in cholesterol values was achieved. Since this type of treatment must be on going in order to be medically effective, issues of patient compliance in the long run are critical. Increasing palatability of a medicine, or presenting together with food, are important in this context too.
- a method of solidifying liquid oils is effected by mixing at least one liquid oil and at least one solid fat, thereby forming a mixture of same and further by transforming the mixture into a homogeneous consistency.
- composition of matter that includes a mixture of at least one liquid oil and at least one solid fat.
- composition of matter that includes a mixture of at least one ethyl ester of a natural fatty acid (which is a liquid oil) and at least one solid fat.
- a method of using at least one liquid oil for a purpose such as, but not limited to, nutritional supplementation, cosmetic treatment, use as a food additive, medical treatment, medical prophylaxis and/or cosmetic prophylaxis.
- the method according to this aspect of the present invention is effected by using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the purpose.
- the use may include, but is not limited to, ingestion and/or external application.
- a method of using at least one liquid oil for prevention or treatment of a medical condition such as, but not limited to, cancer, hypertriglyceridemia, hypo HDL, high cholesterol, hyperinsulinemia and/or hyperglycemia.
- the method according to this aspect of the present invention is effected by using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the prevention or treatment.
- the use may include, but is not limited to, ingestion and/or external application.
- the composition of matter has a homogeneous consistency.
- homogeneous consistency can be achieved by, for example, heating the mixture of oil and fat to a temperature above the melting temperature of the fat, e.g., 40-100° C., and thereafter gradually cooling the mixture to room temperature.
- the liquid oil(s), which is the constituent of therapeutic value is at least 50%, preferably at least 60%, more preferably, at least 70%, most preferably at least 80% of the solidified mixture by weight. It will, however, be appreciated that sufficient percentage of fat(s) should be employed to achieve solidification at at least a portion of the temperature range of 4° C. and 25° C.
- composition of matter according to preferred embodiments of the present invention preferably includes in addition to oil(s) and fat(s) at least one additional ingredient, such as, but not limited to, at least one flavoring agent and/or at least one odorant.
- Extracts of such flavoring agents and odorants are well known in the art.
- Such agents or odorants come in many forms ranging from powders to liquid extracts. They are typically used in minute quantities, typically fractions of percents up to a few percents by weight, to alter a taste and/or the odor of foods.
- the solid fat(s) can be on any type that complies with the above definition, such as, but not limited to bee wax, propolis, butter, artificially hydrogenated vegetable oil, palm oil, cocoa butter, rendered animal fat and/or lanolin.
- the solid fat can include a synthetic polyester of fatty acids and a saccharide, such as, but not limited to, sorbitol, glucose, fructose, lactose, mannose, r1bose or deoxyribose.
- the fatty acid is preferably polypalmitate and polystearate, whereas the saccharide is preferably sucrose.
- the liquid oil(s) fraction of the solidified mixture according to the present invention preferably includes substantial amounts, say 20-90% by weight, of ⁇ -3 PUFA.
- the liquid oil employed can be ⁇ -3 PUFA enriched fish oil, e.g., above 50%, preferably about 80% by weight ⁇ -3 PUFA.
- the liquid oil employed can be ⁇ -3 PUFA enriched fish oil.
- the liquid oil(s) fraction of the solidified mixture according to the present invention preferably includes substantial amounts, say 20-90% by weight, of ⁇ -tocopherol (vitamin E).
- ⁇ -tocopherol (vitamin E, Sigma, St. Louis, Mo.) was mixed with 2 grams sucrose polyester (Olestra; Procter and Gamble, Mason, Ohio) and warmed to 80° C., under a nitrogen atmosphere, to produce a homogenous mixture. Upon cooling to room temperature the mixture solidified. The weight percent of vitamin E in this mixture is 83%.
- mice All mice were kept in filter-covered plastic cages (10 mice per cage) and were fed ad libitum with a basal oil-free standard diet supplemented with 5% by weight of either bee wax solidified fish oil (FO) or bee wax solidified soybean oil (SO).
- FO bee wax solidified fish oil
- SO bee wax solidified soybean oil
- mice were inoculated in the footpad with 5 ⁇ 10 5 cells per mouse in 50 ⁇ l sterile phosphate buffered saline—(PBS). Tumor size was monitored with a Varnier caliber. As described by Elsenbach et al, when local tumor reached a diameter of 8-9 mm, the tumor bearing leg was removed by amputation after ligation above the knee joint. Twenty eight days after amputation the surviving mice were sacrificed and lungs were assessed for metastatic load by weighing and further by histological examination.
- test and control groups 21 ambulatory patients, age 48-71 years (15 men and 6 women) with hyperlipidemia were divided in two groups (test and control groups), took part in this study.
- the test group (10 men and 2 women) consumed 5 grams per day of solidified fish oil in the form described under Example 1 above, while the control group (7 patients) consumed the same amount of an isocaloric placebo in which the fish oil was replaced by olive oil as described under Example 3 above.
- Fasting blood samples were drawn at 0 and 42 days for analysis (see Table 1 below).
- Triglycerides were determined by an enzymatic procedure with a commercial kit (Triglycenrides Enzymatiques PAP 1000, Bio-Merieux, Charbonnieres-les-Bains, France).
- Total cholesterol was determined in serum by an enzymatic calorimeter method according to Siedel et al, ( Clin. Chem. (19S83) 29:1075) using a commercially available kit (Monotest Cholesterol, Bohringer Diagnostica, GmbH, Mannheim, FRG).
- HDL High-density lipoprotein
- Insulin level was determined in the serum by a double antibody radioimmunoassay, using 125 I-labeled human insulin (Pharmacia Diagnosis AB, Uppsala, Sweden).
- Glucose was determined according to Pennock et al, ( Clin. Chi. Acta (1973) 48:193).
Abstract
A method of solidifying liquid oils is disclosed. The method is effected by (a) mixing at least one liquid oil and at least one solid fat, thereby forming a mixture of the at least one liquid oil and the at least one solid fat; and (b) transforming the mixture into a homogeneous consistency. Further disclosed are compositions of matter having a semi-solid texture including at least one liquid oil and at least one solid fat and uses thereof in therapy and cosmetic applications.
Description
- The present invention relates to a method of solidifying at least one oil by the addition of at least one solid fat and, more particularly, to a method of forming a semi-solid paste containing a high concentration of an oil which is normally liquid. The present invention further relates to a soft solid mixture which typically includes 50% or more ethyl esters of natural fatty acids and 50% or less solid fat and, more particularly, to a semi-solid mixture containing fish oil or another source of fat soluble vitamins, including, but not limited to, purified vitamin E. The present invention further relates to a method of using an oil for purposes including, but not limited to, nutritional supplementation, cosmetic treatment, and medical treatment.
- Most fats which are nutritionally important substances exist as fluid oils. Their handling, storage and application is therefore limited to containers (e.g., cooking oil) or capsules (e.g., vitamin E). In principle, such oils can be handled in a solidified form by the addition of large excess of solids like starch, calcium carbonate, lactose etc., which is a common practice in the pharmaceutical industry. After addition of solids, the oils may be pressed into tablets. Owing to the physical size limit of tablets or capsules designed to be consumed by humans, high dose therapy with purified vitamin E, or with substances such as wheat germ oil or fish oil has been problematic because treatment regimens require daily consumption of tens of tablets or capsules. Much of the problem stems not from the efficacy of the therapeutic oil, but from poor patient compliance with treatment protocols requiring intake of large numbers of tablets or capsules each day. The root of this compliance problem lies in the fact that preparation of soft-solid mixtures which contain dietary oil at a concentration above 50% while the solidifying agent is biologically compatible, are not taught by prior art.
- There is increasing evidence that vitamin E, or fish oil which is rich in omega-3 polyunsaturated fatty acids (Ω-3 PUFA), can be used advantageously to treat or prevent a wide range of conditions including, but not limited to, excess gastric acid secretion, blood clotting, arterial thrombogenesis, various types of cancer, hepatitis, depression, high blood pressure, and heart disease (Riber et al, Scand J Gastroenterol (1999) 34:845-8; Saldeen et al, J Am Coll Cardiol (1999) 34:1208-15; Ferguson L R, Mutat Res (1999) 428:329-38; Look et al, Antiviral Res (1999) 43:113-22; Kolleck et al, Free Radic Biol Med (1999) 27:882-90; Shibata et al, J Epidemjol (1999) 9:261-7; Cham et al, Clin Chim Acta (1999) 287:45-57; Yosefy et al, Prostaglandins Leukot Essent Fatty Acids (1999) 61:83-7; Hardman et al, Br J Cancer (1999) 81:440-8; Barber M D, BMJ (1999) 319(7203):187; Adams et al, Am Fam Physician (1999) 60:895-904; Barber et al., Br J Cancer (1999) 81:80-6; Latham et al, Biochem Soc Trans (1998) 26:S158; Bang H O, Compr Ther (1990) 16:31-5; Urakaze et al J Hum Hypertens (1989) 3:277-8)
- Unfortunately, many patients suffering from diseases which may be treated by nutritionally important oils suffer from nausea and reduced appetite. These patients are especially unlikely to comply with treatment protocols which include ingestion of large numbers of pills or tablets each day.
- There is thus a widely recognized need for, and it would be highly advantageous to have, nutritionally or medically important oils at high concentration in a semi-solid form in order to facilitate better patient compliance with proposed treatment regimens,
- According to one aspect of the present invention there is provided a method of solidifying liquid oils, the method comprising the steps of (a) mixing at least one liquid oil and at least one solid fat, thereby forming a mixture of the at least one liquid oil and the at least one solid fat; and (b) transforming the mixture into a homogeneous consistency.
- According to another aspect of the present invention there is provided a composition of matter comprising a mixture of at least one liquid oil and at least one solid fat.
- According to yet another aspect of the present invention there is provided a composition of matter comprising a mixture of at least one ethyl ester of a natural fatty acid and at least one solid fat.
- According to still another aspect of the present invention there is provided a method of using at least one liquid oil for a purpose selected from the group consisting of nutritional supplementation, cosmetic treatment, use as a food additive, medical treatment, medical prophylaxis and cosmetic prophylaxis, the method comprising the steps of using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the purpose.
- According to an additional aspect of the present invention there is provided a method of using at least one liquid oil for prevention or treatment of a medical condition selected from the group consisting of cancer, hypertriglyceridemia, hypo HDL, high cholesterol, hyperinsulinemia and hyperglycemia, the method comprising the step of using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the prevention or treatment.
- According to further features in preferred embodiments of the invention described below, the composition of matter has a homogeneous consistency.
- According to still further features in the described preferred embodiments the at least one liquid oil is at least 50% of the mixture by weight.
- According to still further, features in the described preferred embodiments the composition of matter further comprising at least one additional ingredient.
- According to still further features in the described preferred embodiments the at least one additional ingredient includes at least one flavoring agent.
- According to still further features in the described preferred embodiments the at least one additional ingredient includes at least one odorant.
- According to still further features in the described preferred embodiments the at least one solid fat is selected from a group of solid fats consisting of bee wax, propolis, butter, artificially hydrogenated vegetable oil, palm oil, cocoa butter, rendered animal fat and lanolin.
- According to still further features in the described preferred embodiments the at least one solid fat is a synthetic polyester of fatty acids and a saccharide.
- According to still further features in the described preferred embodiments the saccharide is selected from the group of saccharides consisting of sorbitol, glucose, fructose, lactose, mannose, ribose and deoxyribose.
- According to still further features in the described preferred embodiments the at least one solid fat is a mixture of saccharide is sucrose and further wherein the fatty acid is selected from the group consisting of polypalmitate and polystearate.
- According to still further features in the described preferred embodiments the at least one liquid oil includes omega-3 polyunsaturated fatty acids (Ω-3 PUFA).
- According to still further features in the described preferred embodiments the at least one liquid oil includes α-tocopherol (vitamin E).
- The present invention successfully addresses the shortcomings of the presently known configurations by providing nutritionally or medically important liquid oils at high concentration In a semi-solid form in order to facilitate better patient compliance with proposed treatment regimens.
- The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
- In the drawing:
-
FIG. 1 is a bar-graph presenting the effect of consuming a bee wax solidified fish oil containing 60% Ω-3 PUFA according to t present invention on lung metastasis. Mice (C57BL/6J) were kept in filter-covered plastic cages (10 mice per cage) and were fed ad libitum with a basal oil-free standard diet supplemented with 5% by weight of either bee wax solidified fish oil (FO) or bee wax solidified soybean oil (SO). After two weeks mice were inoculated in the footpad with 5×105 cells of a highly metastatic clone (D 122) of the 3LL Lewis Lung Carcinoma cell line (Elsenbach et al, Int. J. Cancer (1993) 32:113-120) per mouse in 50 μl sterile phosphate buffered saline (PBS). When primary tumor reached a diameter of 8-9 mm, as was deter-mined using a Varnier caliber, the tumor bearing leg was removed by amputation after ligation above the knee joint. Twenty eight days after amputation, the surviving mice were sacrificed and lungs were assessed for metastatic load by weighing. - The present invention is directed to methods for producing mixtures containing typically greater than 50% liquid oil(s) which are semi-solid or solid at room temperature and/or when refrigerated by household means. The present invention is further directed to compositions of matter containing typically greater than 50% liquid oil which are semi-solid or solid at room temperature and/or when refrigerated by household means. The present invention is further of methods of medical treatment, prophylaxis, nutritional supplementation or cosmetic treatment which employ compositions of matter containing greater than 50% oil which are semi-solid or solid at room temperature and/or when refrigerated by household means. Specifically, the present invention can be used to increase patient compliance in therapy regimens requiring consumption of large quantities of oil by allowing preparation and presentation of the material to be ingested in a small volume and in a more palatable form than previously available.
- Before explaining at least one embodiment of the invention detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
- For purposes of this specification and the accompanying claims, the term “liquid oil” refers to an oil which is a liquid in at least a portion of the temperature range of 4-25° C.
- For purposes of this specification and the accompanying claims, the term “solid fat” refers to an oil which is a solid in at least a portion of the temperature range of 4-25° C.
- For purposes of this specification and the accompanying claims, the term “vegetable oil” refers to any oil derived from any part of a plant, including, but not limited to, soybean oil, corn oil, rapeseed oil, olive oil, yam oil, cottonseed oil, walnut oil, peanut oil and almond oil.
- For purposes of this specification and the accompanying claims, the term “artificially hydrogenated” refers to any process by which the degree of saturation of carbon to carbon double bonds may be increased, whether mechanically, physically, or chemically.
- As shown in Example 1 below, one preferred embodiment of the present invention is solidification of fish oil by bee wax to produce a mixture containing about 80% Ω-3 PUFA. A patient requiring a daily dose of 6 grams of Ω-3 PUFA would therefore need to consume 10-12 grams of the resultant semi-solid paste. This portion of semi-solid paste would take the place of, for example, 20 capsules which typically contain about 300 mg Ω-3 PUFA.
- A 10-12 gram portion of solidified fish oil paste could be ingested, for example, by spreading it upon a single slice of bread. According to alternate embodiments, the semi-solid paste might be mixed with flavoring agents, including, but not limited to, smoked salmon flavor, or parmesan cheese flavor, to render it more palatable. Alternately, odorants, such as garlic scent or oregano scent might be added to increase palatability.
- As shown in Example 4 below, purified vitamin E may be similarly solidified by combining it with a low calorie fat substitute. Advantages of using a low calorie fat substitute in compositions of matter of the present invention include, but are not limited to, keeping total caloric intake of a patient as low as possible.
- Myriad medical conditions may be treated using oils as dietary supplements. Examples 5 and 6 describe treatment of a cancer (in an animal model) and hyperlipidemia, respectively. These embodiments are presented as examples of a wide range of possible benefits from the present invention.
- Example 5 describes reduced tumor growth, mortality and metastatic growth in a well established murine lung cancer model in response to dietary supplementation with solidified fish oil prepared according to the method of the present invention. Extrapolation of the results to human patients suggests tremendous potential benefit. With respect to cancer patients, the method of the present invention is especially important, since these patients tend to suffer from decreased appetite and nausea. It is therefore especially important to increase palatability of medication in order to elicit compliance with a proposed treatment regimen.
- Example 6 describes the effects of administration of solidified fish oil according to the present invention to human subjects to control hyperlipidemia. After 6 weeks, treatment induced a significant reduction in triglycerides, cholesterol, insulin and glucose was observed. A concurrent increase in HDL and decrease in cholesterol values was achieved. Since this type of treatment must be on going in order to be medically effective, issues of patient compliance in the long run are critical. Increasing palatability of a medicine, or presenting together with food, are important in this context too.
- Thus, according to one aspect of the present invention there is provided a method of solidifying liquid oils. The method according to this aspect of the present invention is effected by mixing at least one liquid oil and at least one solid fat, thereby forming a mixture of same and further by transforming the mixture into a homogeneous consistency.
- According to another aspect of the present invention there is provided a composition of matter that includes a mixture of at least one liquid oil and at least one solid fat.
- According to yet another aspect of the present invention there is provided a composition of matter that includes a mixture of at least one ethyl ester of a natural fatty acid (which is a liquid oil) and at least one solid fat.
- According to still another aspect of the present invention there is provided a method of using at least one liquid oil for a purpose, such as, but not limited to, nutritional supplementation, cosmetic treatment, use as a food additive, medical treatment, medical prophylaxis and/or cosmetic prophylaxis. The method according to this aspect of the present invention is effected by using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the purpose. The use may include, but is not limited to, ingestion and/or external application.
- According to an additional aspect of the present invention there is provided a method of using at least one liquid oil for prevention or treatment of a medical condition such as, but not limited to, cancer, hypertriglyceridemia, hypo HDL, high cholesterol, hyperinsulinemia and/or hyperglycemia. The method according to this aspect of the present invention is effected by using a composition of matter including a mixture of at least one liquid oil and at least one solid fat for accomplishing the prevention or treatment. The use may include, but is not limited to, ingestion and/or external application.
- According to a preferred embodiment of the present invention the composition of matter has a homogeneous consistency. Such homogeneous consistency can be achieved by, for example, heating the mixture of oil and fat to a temperature above the melting temperature of the fat, e.g., 40-100° C., and thereafter gradually cooling the mixture to room temperature.
- According to preferred embodiments of the present invention the liquid oil(s), which is the constituent of therapeutic value, is at least 50%, preferably at least 60%, more preferably, at least 70%, most preferably at least 80% of the solidified mixture by weight. It will, however, be appreciated that sufficient percentage of fat(s) should be employed to achieve solidification at at least a portion of the temperature range of 4° C. and 25° C.
- The composition of matter according to preferred embodiments of the present invention preferably includes in addition to oil(s) and fat(s) at least one additional ingredient, such as, but not limited to, at least one flavoring agent and/or at least one odorant. Extracts of such flavoring agents and odorants are well known in the art. Such agents or odorants come in many forms ranging from powders to liquid extracts. They are typically used in minute quantities, typically fractions of percents up to a few percents by weight, to alter a taste and/or the odor of foods.
- The solid fat(s) can be on any type that complies with the above definition, such as, but not limited to bee wax, propolis, butter, artificially hydrogenated vegetable oil, palm oil, cocoa butter, rendered animal fat and/or lanolin. Alternatively or in addition the solid fat can include a synthetic polyester of fatty acids and a saccharide, such as, but not limited to, sorbitol, glucose, fructose, lactose, mannose, r1bose or deoxyribose. The fatty acid is preferably polypalmitate and polystearate, whereas the saccharide is preferably sucrose.
- The liquid oil(s) fraction of the solidified mixture according to the present invention preferably includes substantial amounts, say 20-90% by weight, of Ω-3 PUFA. Thus, the liquid oil employed can be Ω-3 PUFA enriched fish oil, e.g., above 50%, preferably about 80% by weight Ω-3 PUFA. Thus, the liquid oil employed can be Ω-3 PUFA enriched fish oil.
- Alternatively, the liquid oil(s) fraction of the solidified mixture according to the present invention preferably includes substantial amounts, say 20-90% by weight, of α-tocopherol (vitamin E).
- Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
- Reference is now made to the following examples, which, together with the above descriptions, illustrate the invention in a non-limiting fashion.
- Generally, the nomenclature used herein and the laboratory procedures described hereinbelow are those well known and commonly employed in the art. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
- Eighty grams of bee wax (Colmeia do Mato Grosso, Mato Grosso, Brasil) was warmed to 80° C. and mixed, under a nitrogen atmosphere, with 400 grams fish oil (EPAX7010 triglycerides, Pronova Biocare a.s. Sandeford, Norway). The mixture was mechanically stirred until a homogeneous consistency was obtained. Upon cooling to 25° C., the mixture solidified to form a homogeneous semi-solid paste. The weight percent of the fish oil in this mixture is 83%. This material was subsequently employed in Examples 5 and 6.
- Eighty grams of bee wax (Colmeia do Mato Grosso, Mato Grosso, Brasil) was warmed to 80° C. and mixed, under a nitrogen atmosphere, with 400 grams soybean oil (from the market). The mixture was mechanically stirred until a homogeneous consistency was obtained. Upon cooling to 25° C., the mixture solidified to form a homogenous semi-solid paste. The weight percent of the oil in this mixture is 80%. This material was subsequently employed as control in Example 5.
- Eighty grams of bee wax (Colmeia do Mato Grosso, Mato Grosso, Brasil) was warmed to 80° C. and mixed, under a nitrogen atmosphere with 400 grams olive oil (from the market). The mixture was mechanically stirred until a homogeneous consistency was obtained. Upon cooling to 25° C., the mixture solidified to form a homogeneous semi-solid paste. The weight percent of the oil in this mixture is 80%. This material was subsequently employed as control in Example 6.
- Ten grams of α-tocopherol (vitamin E, Sigma, St. Louis, Mo.) was mixed with 2 grams sucrose polyester (Olestra; Procter and Gamble, Mason, Ohio) and warmed to 80° C., under a nitrogen atmosphere, to produce a homogenous mixture. Upon cooling to room temperature the mixture solidified. The weight percent of vitamin E in this mixture is 83%.
- Using previously published methods for monitoring tumor progression and metastatic growth (Yam et al, Nutritional Bioch. (1979) 8:619-622) the effect of solidified fish oil prepared as is described under Example 1 on mice (C57BL/6J) bearing a well characterized Lewis Lung Carcinoma (3LL) was studied in comparison to control mice of the same strain and to mice (C57BL/6J) bearing the well characterized Lewis Lung Carcinoma (3LL) fed with solidified soybean oil as is described under Example 2
- All mice were kept in filter-covered plastic cages (10 mice per cage) and were fed ad libitum with a basal oil-free standard diet supplemented with 5% by weight of either bee wax solidified fish oil (FO) or bee wax solidified soybean oil (SO).
- After two weeks of ad libitum feeding with these diets, tumor inoculation was conducted using a highly metastatic clone (D 122) of the 3LL Lewis Lung Carcinoma cell line (Eisenbach et al, Int. J. Cancer (1993) 32:113-120). To this end, mice were inoculated in the footpad with 5×105 cells per mouse in 50 μl sterile phosphate buffered saline—(PBS). Tumor size was monitored with a Varnier caliber. As described by Elsenbach et al, when local tumor reached a diameter of 8-9 mm, the tumor bearing leg was removed by amputation after ligation above the knee joint. Twenty eight days after amputation the surviving mice were sacrificed and lungs were assessed for metastatic load by weighing and further by histological examination.
- Significantly slower growth of primary tumor, lower mortality rate and lower metastatic spread were observed in mice fed with fish oil (FO) in comparison with mice fed with soybean oil (SO). The results of lung weights are summarized in
FIG. 1 . - Patients and Methods: 21 ambulatory patients, age 48-71 years (15 men and 6 women) with hyperlipidemia were divided in two groups (test and control groups), took part in this study. The test group (10 men and 2 women) consumed 5 grams per day of solidified fish oil in the form described under Example 1 above, while the control group (7 patients) consumed the same amount of an isocaloric placebo in which the fish oil was replaced by olive oil as described under Example 3 above. Fasting blood samples were drawn at 0 and 42 days for analysis (see Table 1 below).
- Blood Analysis: Part of the blood was transferred to precooled centrifuge tubes containing fluoride-oxalate and centrifuged at 1,500 r.p.m. or 10 minutes and plasma was collected and frozen.
- Triglycerides were determined by an enzymatic procedure with a commercial kit (
Triglycenrides Enzymatiques PAP 1000, Bio-Merieux, Charbonnieres-les-Bains, France). - Total cholesterol was determined in serum by an enzymatic calorimeter method according to Siedel et al, (Clin. Chem. (19S83) 29:1075) using a commercially available kit (Monotest Cholesterol, Bohringer Diagnostica, GmbH, Mannheim, FRG).
- High-density lipoprotein (HDL) was analyzed according to Lopes-Virtlla et al, (Clin. Chim. (1977) 23:882).
- Insulin level was determined in the serum by a double antibody radioimmunoassay, using 125I-labeled human insulin (Pharmacia Diagnosis AB, Uppsala, Sweden).
- Glucose was determined according to Pennock et al, (Clin. Chi. Acta (1973) 48:193).
- The results are Summarized in Table 1 below.
TABLE 1 Values* of Plasma Triglycerides, Cholesterol, LDL-Cholesterol Insulin and Glucose at Day 0 and After 42 Days Test Group Control Group 0 days 42 days 0 days 42 days Triglycerides 240 ± 39 180 ± 18 230 ± 35 220 ± 42 (mg/dl) Cholesterol 270 ± 39 230 ± 19 280 ± 36 260 ± 28 (mg/dl) HDL-Cholesterol 30 ± 13 48 ± 816 32 ± 15 35 ± 17 (mg/dl) Insulin (μU/ml) 31 ± 13 18 ± 8 30 ± 14 31 ± 17 Glucose (mg/dl) 142 ± 18 95 ± 15 128 ± 22 126 ± 22
*Mean ± S.D.
- The results of the blood biochemistry presented in Table 1 above indicate that the solidified fish oil treatment induced a significant reduction in triglycerides, cholesterol, insulin and glucose and an increase in HDL-cholesterol values after 42 days of treatment. No significant changes were observed in the control group. No negative side effects were observed in either group.
- Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Claims (20)
1. A composition of matter that is semi-solid or solid at room temperature and/or when refrigerated by household means, consisting essentially of an edible liquid oil that is liquid within the entire range of 4-25° C. and a sufficient amount of beeswax such that the composition of matter is semi-solid or solid at room temperature and/or when refrigerated by household means, the amount of said oil being at least 50% by weight and the amount of said beeswax being less than 50% by weight.
2. A composition of matter according to claim 1 , wherein said at least one liquid oil contains omega-3 polyunsaturated fatty acids (Ω-3 PUFA).
3. A composition of matter according to claim 2 , wherein said at least one liquid oil in the solidifying mixture contains from about 20% to about 90% by weight of omega-3 polyunsaturated fatty acids.
4. A composition of matter according to claim 3 , wherein said at least one liquid oil containing 20-90% by weight of omega-3 polyunsaturated fatty acids is fish oil.
5. A composition of matter according to claim 4 , wherein said fish oil contains above 50% by weight of omega-3 polyunsaturated fatty acids.
6. A composition of matter according to claim 1 , wherein said at least one liquid oil is a vegetable oil.
7. A composition of matter according to claim 6 , wherein said at least one vegetable oil is selected from soybean oil and olive oil.
8. A composition of matter according to claim 4 , comprising from 50% to about 83% of by weight of fish oil.
9. A composition of matter according to claim 4 , comprising about 80% by weight of fish oil.
10. A composition of matter according to claim 9 , wherein the amount of omega-3 polyunsaturated fatty acids in said fish oil is such that said composition comprises about 60% by weight of omega-3 polyunsaturated fatty acids.
11. A composition of matter according to claim 7 , wherein said vegetable oil is soybean oil.
12. A composition of matter according to claim 7 , wherein said vegetable oil is olive oil.
13. A composition of matter according to claim 1 , wherein the composition has a homogeneous consistency.
14. A composition of matter according to claim 1 , in the form of a homogeneous semi-solid spreading paste.
15. A composition of matter according to claim 1 , further comprising at least one additional ingredient.
16. A composition of matter according to claim 15 , wherein said at least one additional ingredient is at least one flavoring agent.
17. A composition of matter according to claim 15 , wherein said at least one additional ingredient is at least one odorant.
18. A method for the preparation of a composition of matter according to claim 1 , the method comprising:
(a) heating a mixture of said at least one liquid oil and said beeswax to a temperature above the melting point of said beeswax, under conditions such that homogeneous consistency is obtained; and
(b) gradually cooling said mixture to room temperature, thus obtaining a homogeneous semi-solid paste that can be stored at room temperature and/or by household refrigerating.
19. A homogeneous semi-solid paste suitable for spreading comprising at least 50% by weight of fish oil and from 17% to about 50% of beeswax, said homogeneous semi-solid paste being formed by a method comprising:
(a) mixing fish oil with beeswax at 80° C. under stirring until a homogeneous consistency is obtained; and
(b) cooling said mixture to room temperature, thus obtaining said homogeneous semi-solid paste suitable for spreading.
20. A nutritional supplement comprising a composition according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/913,428 US20050014825A1 (en) | 1998-10-25 | 2004-08-09 | Preparation and use of solidified oils |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL126741 | 1998-10-25 | ||
IL12674198A IL126741A0 (en) | 1998-10-25 | 1998-10-25 | Solidification of fluid oils and their use |
US09/830,357 US6773715B1 (en) | 1998-10-25 | 1999-10-25 | Preparation and use of solidified oils |
US10/913,428 US20050014825A1 (en) | 1998-10-25 | 2004-08-09 | Preparation and use of solidified oils |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1999/000564 Continuation WO2000024360A2 (en) | 1998-10-25 | 1999-10-25 | Preparation and use of solidified oils |
US09/830,357 Continuation US6773715B1 (en) | 1998-10-25 | 1999-10-25 | Preparation and use of solidified oils |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050014825A1 true US20050014825A1 (en) | 2005-01-20 |
Family
ID=11072064
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/830,357 Expired - Fee Related US6773715B1 (en) | 1998-10-25 | 1999-10-25 | Preparation and use of solidified oils |
US10/913,428 Abandoned US20050014825A1 (en) | 1998-10-25 | 2004-08-09 | Preparation and use of solidified oils |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/830,357 Expired - Fee Related US6773715B1 (en) | 1998-10-25 | 1999-10-25 | Preparation and use of solidified oils |
Country Status (11)
Country | Link |
---|---|
US (2) | US6773715B1 (en) |
EP (1) | EP1123008A4 (en) |
JP (1) | JP2002537411A (en) |
CN (1) | CN1636021A (en) |
AU (1) | AU6485499A (en) |
BR (1) | BR9914800A (en) |
CA (1) | CA2346820A1 (en) |
IL (1) | IL126741A0 (en) |
MX (1) | MXPA01004090A (en) |
NO (1) | NO20012011L (en) |
WO (1) | WO2000024360A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188460A1 (en) * | 2002-01-11 | 2006-08-24 | Helen Ambrosen | Solid hair conditioning product |
US20070151800A1 (en) * | 2005-12-29 | 2007-07-05 | 3M Innovative Properties Company | Porous membrane |
FR2943891A1 (en) * | 2009-04-03 | 2010-10-08 | Sas Genialis | Gellified fatty substance, useful in mayonnaise and spreads, comprises liquid fatty substance having triacylglycerols and fatty acids, and beeswax |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL133968A0 (en) * | 2000-01-10 | 2001-04-30 | Thixo Ltd | Therapeutic oils and edible pastes containing the same |
AU2001273028B2 (en) | 2000-06-26 | 2006-11-16 | Dsm Ip Assets B.V. | Improved methods of incorporating polyunsaturated fatty acids in milk |
US7001889B2 (en) | 2002-06-21 | 2006-02-21 | Merial Limited | Anthelmintic oral homogeneous veterinary pastes |
US8221809B2 (en) | 2006-06-22 | 2012-07-17 | Martek Biosciences Corporation | Encapsulated labile compound compositions and methods of making the same |
KR101650680B1 (en) * | 2007-08-31 | 2016-08-23 | 디에스엠 아이피 어셋츠 비.브이. | Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof |
JP5293221B2 (en) * | 2008-02-08 | 2013-09-18 | 不二製油株式会社 | Fat and oil crystallization accelerator |
US20120027893A1 (en) | 2009-03-30 | 2012-02-02 | Trident Seafoods Corporation | Viscous liquid dietary supplement for animals |
EP2340721B1 (en) * | 2009-12-21 | 2012-12-12 | Alexander Gertz | Additive for improving the consistency of frying, baking, boiling and/or deep frying oils/ fats |
GB201001412D0 (en) * | 2010-01-28 | 2010-03-17 | Natures Lab Ltd | Propolis and process for the treatment thereof |
CN102318797A (en) * | 2011-07-20 | 2012-01-18 | 博格斯股份有限公司 | Culinary food ingredient and preparation method thereof in the cooker |
JP2014011962A (en) * | 2012-07-03 | 2014-01-23 | Fuji Oil Co Ltd | Method of accelerating crystallization of oil and fat |
CN105010575A (en) * | 2015-07-30 | 2015-11-04 | 杭州恒华食品有限公司 | Margarine without trans-fatty acid and preparation method of the margarine without trans-fatty acid |
CN109329503B (en) * | 2018-12-10 | 2021-09-24 | 青岛三味香道文化传播有限公司 | Tea balm, green tea balm and preparation method thereof |
CN116649429A (en) * | 2023-04-24 | 2023-08-29 | 广东海洋大学 | Liquid oil gel with high unsaturation degree and preparation and application thereof |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3102814A (en) * | 1961-03-10 | 1963-09-03 | Lever Brothers Ltd | Shortening |
US3132951A (en) * | 1961-04-04 | 1964-05-12 | Lever Brothers Ltd | Plastic shortening |
US3253927A (en) * | 1963-05-15 | 1966-05-31 | Procter & Gamble | Plastic shortening |
US4587124A (en) * | 1984-10-25 | 1986-05-06 | Kim Tuk M | Composition for treating cutaneous wounds |
US5064677A (en) * | 1987-08-19 | 1991-11-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-containing product and process for preparing same |
US5130151A (en) * | 1990-12-26 | 1992-07-14 | Megafoods, Inc. | Natural and synthetic edible moisture barrier |
US5248509A (en) * | 1987-08-19 | 1993-09-28 | Van Den Bergh Foods Co., | Food product containing oil-soluble vitamins, digestible fat and indigestible polyol fatty acid polyesters |
US5268196A (en) * | 1988-05-30 | 1993-12-07 | Ford Motor Company | Process for forming anti-reflective coatings comprising light metal fluorides |
US5472728A (en) * | 1994-04-22 | 1995-12-05 | Kraft Foods, Inc. | Edible fat-containing margarine type products and process for preparing same |
US5514407A (en) * | 1992-05-15 | 1996-05-07 | Brandeis University | Modified fat blends |
US5624703A (en) * | 1992-05-15 | 1997-04-29 | Brandeis University | Modified fat blends |
US5817322A (en) * | 1995-09-14 | 1998-10-06 | Xu; Rongxiang | Pharmaceutical base and the use of the same |
US5885559A (en) * | 1996-09-06 | 1999-03-23 | Colgate Palmolive Company | Solid cosmetic composition containing hexanediol-behenyl beeswax as gelling agent |
US5908377A (en) * | 1995-01-30 | 1999-06-01 | Fukuda; Tomoyuki | Method of solidifying liquid oils |
US6020020A (en) * | 1995-11-24 | 2000-02-01 | Loders-Croklaan B.V. | Composition based on fish oil |
US6099866A (en) * | 1986-01-31 | 2000-08-08 | Slimak; K. M. | Compositions for topical application and other products from fresh beeswaxes |
US6117476A (en) * | 1999-01-04 | 2000-09-12 | Shaul Eger | Healthy food spreads |
US6123979A (en) * | 1997-10-24 | 2000-09-26 | Unilever Patent Holdings Bv | Wax ester compositions |
US6159525A (en) * | 1995-11-14 | 2000-12-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-spread |
US6162483A (en) * | 1996-11-04 | 2000-12-19 | Raisio Benecol Ltd. | Fat compositions for use in food |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB422940A (en) * | 1932-12-10 | 1935-01-22 | Kerasin Ltd | Process of producing cosmetic salves or basic substances for salves |
ES336574A1 (en) * | 1966-03-08 | 1968-08-16 | Grace W R & Co | A method of preparing a plastic low-fat content food spread |
US4789664A (en) * | 1986-12-19 | 1988-12-06 | The Procter & Gamble Company | Food compositions with superior blood cholesterol lowering properties |
US4973489A (en) * | 1987-05-13 | 1990-11-27 | Curtice Burns, Inc. | Polysaccaride fatty acid polyester fat substitutes |
GB8804571D0 (en) * | 1988-02-26 | 1988-03-30 | Dairy Crest Ltd | Low fat spread |
US5268186A (en) * | 1988-11-14 | 1993-12-07 | Fries & Fries, Inc. | Product and process of making heat stable flavors containing fatty acids |
JPH07292385A (en) * | 1994-03-04 | 1995-11-07 | Yoshihide Hagiwara | Antioxidant for fish oil |
JP3364544B2 (en) * | 1994-11-25 | 2003-01-08 | キユーピー株式会社 | How to prevent browning of dietary supplements |
RO113113B1 (en) * | 1997-05-07 | 1999-04-30 | Felician Titus Stoica | Ointment for treating burns and other skin affections |
-
1998
- 1998-10-25 IL IL12674198A patent/IL126741A0/en unknown
-
1999
- 1999-10-25 EP EP99952770A patent/EP1123008A4/en not_active Withdrawn
- 1999-10-25 JP JP2000577972A patent/JP2002537411A/en active Pending
- 1999-10-25 AU AU64854/99A patent/AU6485499A/en not_active Abandoned
- 1999-10-25 CA CA002346820A patent/CA2346820A1/en not_active Abandoned
- 1999-10-25 WO PCT/IL1999/000564 patent/WO2000024360A2/en not_active Application Discontinuation
- 1999-10-25 MX MXPA01004090A patent/MXPA01004090A/en unknown
- 1999-10-25 BR BR9914800-5A patent/BR9914800A/en not_active IP Right Cessation
- 1999-10-25 CN CNA998125768A patent/CN1636021A/en active Pending
- 1999-10-25 US US09/830,357 patent/US6773715B1/en not_active Expired - Fee Related
-
2001
- 2001-04-24 NO NO20012011A patent/NO20012011L/en not_active Application Discontinuation
-
2004
- 2004-08-09 US US10/913,428 patent/US20050014825A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3102814A (en) * | 1961-03-10 | 1963-09-03 | Lever Brothers Ltd | Shortening |
US3132951A (en) * | 1961-04-04 | 1964-05-12 | Lever Brothers Ltd | Plastic shortening |
US3253927A (en) * | 1963-05-15 | 1966-05-31 | Procter & Gamble | Plastic shortening |
US4587124A (en) * | 1984-10-25 | 1986-05-06 | Kim Tuk M | Composition for treating cutaneous wounds |
US6099866A (en) * | 1986-01-31 | 2000-08-08 | Slimak; K. M. | Compositions for topical application and other products from fresh beeswaxes |
US5064677A (en) * | 1987-08-19 | 1991-11-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-containing product and process for preparing same |
US5248509A (en) * | 1987-08-19 | 1993-09-28 | Van Den Bergh Foods Co., | Food product containing oil-soluble vitamins, digestible fat and indigestible polyol fatty acid polyesters |
US5268196A (en) * | 1988-05-30 | 1993-12-07 | Ford Motor Company | Process for forming anti-reflective coatings comprising light metal fluorides |
US5130151A (en) * | 1990-12-26 | 1992-07-14 | Megafoods, Inc. | Natural and synthetic edible moisture barrier |
US5514407A (en) * | 1992-05-15 | 1996-05-07 | Brandeis University | Modified fat blends |
US5624703A (en) * | 1992-05-15 | 1997-04-29 | Brandeis University | Modified fat blends |
US5472728A (en) * | 1994-04-22 | 1995-12-05 | Kraft Foods, Inc. | Edible fat-containing margarine type products and process for preparing same |
US5908377A (en) * | 1995-01-30 | 1999-06-01 | Fukuda; Tomoyuki | Method of solidifying liquid oils |
US5817322A (en) * | 1995-09-14 | 1998-10-06 | Xu; Rongxiang | Pharmaceutical base and the use of the same |
US6159525A (en) * | 1995-11-14 | 2000-12-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-spread |
US6020020A (en) * | 1995-11-24 | 2000-02-01 | Loders-Croklaan B.V. | Composition based on fish oil |
US5885559A (en) * | 1996-09-06 | 1999-03-23 | Colgate Palmolive Company | Solid cosmetic composition containing hexanediol-behenyl beeswax as gelling agent |
US6162483A (en) * | 1996-11-04 | 2000-12-19 | Raisio Benecol Ltd. | Fat compositions for use in food |
US6123979A (en) * | 1997-10-24 | 2000-09-26 | Unilever Patent Holdings Bv | Wax ester compositions |
US6117476A (en) * | 1999-01-04 | 2000-09-12 | Shaul Eger | Healthy food spreads |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188460A1 (en) * | 2002-01-11 | 2006-08-24 | Helen Ambrosen | Solid hair conditioning product |
US7670998B2 (en) * | 2002-01-11 | 2010-03-02 | Cosmetic Warrior Limited | Solid hair conditioning product |
US20070151800A1 (en) * | 2005-12-29 | 2007-07-05 | 3M Innovative Properties Company | Porous membrane |
US7686132B2 (en) | 2005-12-29 | 2010-03-30 | 3M Innovative Properties Company | Porous membrane |
FR2943891A1 (en) * | 2009-04-03 | 2010-10-08 | Sas Genialis | Gellified fatty substance, useful in mayonnaise and spreads, comprises liquid fatty substance having triacylglycerols and fatty acids, and beeswax |
Also Published As
Publication number | Publication date |
---|---|
EP1123008A4 (en) | 2004-09-01 |
EP1123008A2 (en) | 2001-08-16 |
NO20012011L (en) | 2001-05-29 |
WO2000024360A3 (en) | 2000-08-10 |
AU6485499A (en) | 2000-05-15 |
JP2002537411A (en) | 2002-11-05 |
NO20012011D0 (en) | 2001-04-24 |
US6773715B1 (en) | 2004-08-10 |
CA2346820A1 (en) | 2000-05-04 |
BR9914800A (en) | 2001-11-06 |
CN1636021A (en) | 2005-07-06 |
WO2000024360A8 (en) | 2001-01-18 |
IL126741A0 (en) | 1999-08-17 |
MXPA01004090A (en) | 2002-04-08 |
WO2000024360A2 (en) | 2000-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6773715B1 (en) | Preparation and use of solidified oils | |
DE69920180T2 (en) | PRODUCT AND METHOD OF REDUCING THE STRESS-INDUCED IMMUNO RESTRICTION | |
CA2229624C (en) | Method of reducing bodyweight and treating obesity | |
DE69935995T3 (en) | POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT | |
RU2350124C2 (en) | Nutritious composition for improvement of skin condition and prevention of dermal diseases | |
US20040157932A1 (en) | Supplements and foods comprising oleylethanolamide | |
JPH0716076A (en) | Preparation for smoker | |
JPH044298B2 (en) | ||
JPH0369886B2 (en) | ||
US4855136A (en) | Therapeutic composition and method | |
CN104168772A (en) | Food composition comprising vitamin k and saturated fat and its use | |
CN1679593A (en) | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E | |
IL142754A (en) | Semi-solid or solid compositions comprising a liquid oil and solid fat | |
Lee | Essent ial Fat ty Acids | |
JP2007161703A (en) | Compound with antifatigue effect and compound with endurance-enhancing effect and food/drink containing the same | |
MANSOR et al. | Effect of various dietary pattern on blood pressure management: A review | |
JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
JP4359205B2 (en) | Skin moisturizing food | |
Visioli et al. | The intake of long chain omega 3 fatty acids through fish versus capsules results in greater increments of their plasma levels | |
JP2000239168A (en) | Cerebral apoplexy-preventing agent and composition obtained by blending the same | |
CA1334002C (en) | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals | |
JP3947322B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
JP2023167323A (en) | Oral composition | |
JP2021145563A (en) | Lipid metabolism improving composition | |
JP2020023482A (en) | Peripheral body temperature enhancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |